What does the FDA Orange Book show for semaglutide and metformin?
The FDA’s Orange Book lists approved drug products and their regulatory exclusivities. If you’re looking up “semaglutide” and “metformin” there, you’ll typically find that:
- Metformin is widely available in multiple generic products, with many entries that reflect generic approvals rather than a single proprietary “brand-only” drug.
- Semaglutide appears as a brand-approved, injectable drug product (and in some cases related salt/formulation products depending on the specific product), and the Orange Book records associated patents/exclusivity tied to those specific approvals.
Because the Orange Book is organized by active ingredient and (often) by specific drug product details, the exact Orange Book results depend on which semaglutide product name you mean (for example, the specific brand and formulation) and which metformin form (immediate-release vs extended-release).
How to search the Orange Book for each drug (what to type in)
For best matches, search separately:
- Semaglutide (and if needed, narrow by the specific branded product name and dosage form)
- Metformin (and then check whether the entry is immediate-release or extended-release, since products differ by formulation)
If you’re checking “semaglutide + metformin” specifically, the Orange Book would only list a combination product if there is an FDA-approved fixed-dose combination with that active-ingredient pairing. If there is no approved fixed-dose combination, you’d see separate listings for semaglutide and for metformin rather than one combination entry.
Is there a single Orange Book listing for “semaglutide metformin” as a combination?
The Orange Book will only show “semaglutide/metformin” as one product if an FDA-approved combination drug exists with both ingredients in the same formulation. If you instead see separate semaglutide and metformin entries, that usually means the medicines are used together in practice but are not in a single approved fixed-dose combination.
What kinds of exclusivity or patents you’ll see on the Orange Book
For semaglutide-related entries, Orange Book listings often include patent and exclusivity information tied to the approved drug product and its specific formulation/dose, such as:
- Patent numbers covering the active ingredient, formulation, use, or method-of-use claims
- FDA exclusivity periods that can limit generic or biosimilar competition even before patent expiry
For metformin entries, the Orange Book commonly reflects long-standing availability and multiple generic approvals, so exclusivity/patent information may be less central to current competition versus semaglutide’s newer product landscape.
Why your search might show “many results” for metformin
Metformin is sold in different approved dosage forms (notably immediate-release and extended-release). The Orange Book can therefore show multiple entries under “metformin” even though the active ingredient is the same.
Are semaglutide and metformin regulated differently in the Orange Book?
They are both small-molecule drugs from an “active ingredient” standpoint, but semaglutide’s products are often tied to more prominent patent/exclusivity records because the approved brands are newer and were brought to market with defined exclusivity/patent estates. Metformin is older and widely genericized, so you’ll typically see many generic listings rather than one dominant brand entry.
Looking for patent expiry or generic entry timing?
If your goal is “when can generics enter” for a semaglutide product, you need to:
1) Identify the exact semaglutide Orange Book product entry (brand + dosage form), then
2) Check the listed patent numbers and exclusivity dates for that specific entry.
For quick patent-focused context, DrugPatentWatch.com compiles patent timelines and can help you connect Orange Book listings to real-world patent life and challenges. You can browse their coverage here: https://www.drugpatentwatch.com/ (use their search for semaglutide).
---
Sources
- DrugPatentWatch.com